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Decisions in public health should be based on the best 
available evidence, reviewed and appraised using a 
rigorous and transparent methodology. The Project 
on a Framework for Rating Evidence in Public Health 
(PRECEPT) defined a methodology for evaluating and 
grading evidence in infectious disease epidemiology, 
prevention and control that takes different domains and 
question types into consideration. The methodology 
rates evidence in four domains: disease burden, risk 
factors, diagnostics and intervention. The framework 
guiding it has four steps going from overarching ques-
tions to an evidence statement. In step 1, approaches 
for identifying relevant key areas and developing spe-
cific questions to guide systematic evidence searches 
are described. In step 2, methodological guidance for 
conducting systematic reviews is provided; 15 study 
quality appraisal tools are proposed and an algorithm 
is given for matching a given study design with a tool. 
In step 3, a standardised evidence-grading scheme 
using the Grading of Recommendations Assessment, 
Development and Evaluation Working Group (GRADE) 
methodology is provided, whereby findings are docu-
mented in evidence profiles. Step 4 consists of pre-
paring a narrative evidence summary. Users of this 
framework should be able to evaluate and grade scien-
tific evidence from the four domains in a transparent 
and reproducible way.
Introduction 
The potential fallacies of relying solely on expert opin-
ion to establish best practice in clinical decision-mak-
ing and public health policies are well known globally 
[1]. In guideline development, it is standard practice to 
draw on systematic reviews of the available evidence. 
For evidence of benefits and harms, well conducted 
randomised controlled trials (RCTs) minimise bias and 
systematic reviews of these are commonly used in 
decision-making. However, observational studies are 
important for answering public health questions, not 
least because in many cases they are the only avail-
able or feasible source of empirical evidence [2].
Judging the effectiveness of infectious disease pre-
vention and control interventions creates challenges 
related to the population-level effects and long-term 
aspects of the intervention. In addition, a variety of 
other elements need to be considered in decision-mak-
ing, including disease burden, risk factors for infection 
or mode of transmission. In adopting the concept of 
‘best available evidence’ [3], evaluating the benefits 
and harms along the full causal chain from intervention 
to outcomes within a given context requires a variety of 
fit-for-purpose methods from multiple disciplines.
Although considerable progress has been made 
regarding the use of systematic reviews for public 
health decision-making, the approaches currently used 
for conducting and appraising systematic reviews in 
public health have their limits. They regularly report 
effect estimates and risk of bias, but often do not 
assess the certainty of the evidence for the entire 
body of such across outcomes. Moreover, traditional 
approaches mainly focus on intervention effectiveness 
and safety, but do not provide a generalised approach 
that addresses all factors relevant to decision-making 
in infectious disease prevention and control, such as 
2 www.eurosurveillance.org
the epidemiology, interventions as well as diagnostics 
and risk factors.
New evidence appraisal and grading system 
approaches that incorporate information from stud-
ies with different designs have been developed. The 
most prominent system, developed by the Grading 
of Recommendations Assessment, Development and 
Evaluation Working Group (GRADE) [4], has been widely 
applied in clinical medicine as well as public health. A 
working group established by the European Centre for 
Disease Prevention and Control (ECDC) examined the 
application of GRADE to infectious disease prevention 
and control [5] and initiated the Project on a Framework 
for Rating Evidence in Public Health (PRECEPT). The 
PRECEPT consortium was established in 2012 with rep-
resentatives from European public health agencies, 
academic institutions and ECDC. The first results of 
this project were published earlier [6,7].
An approach to infectious disease prevention and 
control that adheres to the principles of evidence-
based public health, using a defined framework for 
the assessment of the certainty in the evidence, has a 
number of advantages over conventional approaches. 
In particular, such an approach:
• Helps to improve the quality of the resulting public 
health recommendations.
• Reduces anticipated or actual arbitrary decisions.
• Improves transparency.
• Builds trust and supports the acceptance of recom-
mendations by professionals and the public.
• Helps to compare recommendations endorsed by 
different countries or institutions.
Figure 1
Flowchart for working with the PRECEPT methodology
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Figure 2
Overview of the systematic review process
Preparation of the review protocol 
Systematic literature search
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Is it a qualitative study?






























































Use Use Use Use Use
cBAS: controlled before–after study; C–C study: case–control study; cRCT: cluster-randomised controlled trial; ITS: interrupted time series; 
nRCT: non-randomised controlled trial; QAT: quality appraisal tool; RCT: randomised controlled trial; SCCS: self-controlled case series; 
uBAS: uncontrolled before-after study.
a QATs mentioned first are recommended as first choice, whereas those in parentheses can be used alternatively.
b QAT numbers refer to Table 2.
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Figure 4
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GRADE: Grading of Recommendations Assessment, Development and Evaluation Working Group.
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The approach presented here applies the most 
advanced methodology for assessing certainty of 
the evidence, the GRADE methodology. Even though 
the individual elements (e.g. the GRADE methodol-
ogy, PICO question framing and systematic review) of 
the proposed approach are not new, they have never 
been integrated into one comprehensive framework 
that guides users from identification of the relevant 
research questions to preparation of a final evidence 
assessment summary for the area of infectious disease 
prevention and control. Moreover, in contrast to other 
approaches, the framework puts particular emphasis 
on question framing and the selection of appropriate 
risk of bias tools. The framework provides evidence 
assessment guidance in infectious disease epidemi-
ology, prevention and control, but is not designed 
to conduct a rapid assessment for the purpose of 
answering urgent questions in public health crises or 
emergencies.
PRECEPT intends to provide methodological guidance 
for public health agencies, scientists working in the 
field of evidence-based public health, and other insti-
tutions and individuals involved in appraising evidence 
and developing public health guidance with a focus 
on infectious diseases. Here we present an overview 
of the PRECEPT approach (see also Supplementary 
Material [8]).
Domains used in the PRECEPT framework 
The PRECEPT framework focuses on the following four 
domains:
i. Disease burden (significance of the problem), which 
encompasses studies on the incidence, prevalence 
and severity of diseases and complications, as well as 
studies on the perception of diseases in target popula-
tions. For example, what is the incidence of hepatitis B 
in sex workers in eastern European countries?
ii. Infection and disease risk factors (causes of the 
problem), which encompasses studies on preventable 
and non-preventable risk factors for infection, disease 
and complications. For example, is sepsis acquired in 
the neonatal intensive care unit a risk factor for cer-
ebral palsy?
PICO element Suggested adaption/addition according to domain Example
Domain i: Disease burden




PICO question: What is the incidence of hepatitis B in sex workers in Eastern European countries?
Domain ii: Risk factors
Population No adaptation necessary Hospitalised patients
Intervention Exposure or risk factor Prior antibiotic use
Comparator Absence of exposure or risk factor No prior antibiotic use




PICO question: In hospitalised patients, does prior antibiotic use, compared with no prior antibiotic use, pose a risk of carbapenemase-
producing Enterobacteriaceae infection?
Domain iii: Diagnostics
Population No adaptation necessary Children < 5 years of age
Intervention Index test Interferon gamma release assays
Comparator Comparator test Tuberculin skin test
Outcome No adaptation necessary Tuberculosis
PICO question: What is the sensitivity and specificity of interferon gamma release assays compared with the tuberculin skin test for 




Children < 5 years of age
Intervention Infant rotavirus vaccination
Comparator No vaccination
Outcome Diarrhoea
PICO question: In children < 5 years of age, does infant rotavirus vaccination, compared with no vaccination, prevent diarrhoea?
PICO: population, intervention, comparator, outcomes.
Table 1


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































iii. Diagnostics (detection of the problem), which encom-
passes studies on diagnostic accuracy (sensitivity and/
or specificity of diagnostic tests/measures). For exam-
ple, what is the sensitivity and specificity of tests for 
tuberculosis in children?
iv. Interventions (consequences of action against the 
problem), which encompasses studies examining effi-
cacy, effectiveness and adverse effects. For example, 
what is the effectiveness of vaccination of infants 
against rotavirus for the prevention of hospitalisation?
Four-steps to assessing evidence
The general approach to this process of assessing evi-
dence within these four domains consists of four steps 
(Figure 1).
Step 1: Identify the relevant questions
PRECEPT proposes applying the extended Patient/
Population, Intervention, Comparator/Comparison/
Control, and Outcome (PICO) format and integrating 
other questions to the extent possible.
PICO is considered to be the most appropriate way of 
framing questions related to interventions (domain 
(iv)) [2,9]. However, for studies on disease burden 
(domain (i)), it can be changed to focus on population, 
condition (i.e. disease) and context [10]. For risk factors 
(domain (ii)), the PICO format can be easily modified by 
replacing ‘intervention’ with ‘exposure’ and ‘compara-
tor’ with ‘absence of risk factor’. Furthermore, differ-
ent risk factors can be compared with each other (risk 
factor x vs risk factor y) and different risk factor levels 
to establish an exposure–response relationship. For 
diagnostic accuracy studies (domain (iii)), PICO can be 
interpreted as population, index test, comparator test 
and outcome (target condition) [11]. Examples of PICO 
questions for all domains are shown in Table 1.
In infectious disease prevention and control, research-
ers are regularly confronted with complex of ques-
tions that have to be addressed in combination. For 
example, the question, ‘Should vaccination against 
rotavirus be recommended for all infants?’ comprises 
multiple questions from different fields that need to be 
addressed e.g.:
• What is the incidence of rotavirus infection among 
children < 5 years of age?
• Is age a risk factor for rotavirus infection among chil-
dren < 5 years of age?
• What is the effectiveness of vaccination against 
rotavirus?
• What is the risk of intussusception associated with 
the vaccine?
In such situations, developing a logic model (concep-
tual diagram) tends to be helpful [12] to identify and 
prioritise all relevant questions, and to place these 
in context. In systematic reviews, a logic model is a 
graphical representation that helps in scoping the 
review, defining and conducting the review, and mak-
ing results from the review relevant to policy and prac-
tice [13].
Step 2: Perform the systematic review
Evidence should be identified and synthesised using 
a rigorous systematic review process. A systematic 
review usually includes six steps (Step 2.1. to 2.6. as 
parts of step 2 of the PRECEPT workflow, see Figure 2).
For more extensive information on conducting a sys-
tematic review, readers are referred to the literature 
[9,14].
Assessment of methodological quality (risk of 
bias)
For appraising the methodological quality (risk of bias) 
of each study identified during the systematic review, 
the PRECEPT framework proposes using specific qual-
ity appraisal tools (QATs) according to study design [6]. 
A selection of 15 QATs, identified and selected during 
the first phase of the project by applying a system-
atic review-based approach [6], are proposed (Figure 
3,  Table 2). For each study design, the algorithm 
leads to the identification of a single QAT or a group 
of QATs. Risk of bias should be assessed in the form 
of a judgment rather than a score. It is suggested that 
the Cochrane classification scheme for bias is used: (i) 
high risk of bias; (ii) low risk of bias, and (iii) unclear 
risk of bias [14].
Synthesis of data
In the case of quantitative data, data synthesis can be 
conducted using meta-analytic techniques. If statisti-
cal pooling appears to be inappropriate, e.g. if inter-
ventions are too heterogeneous to be grouped in a 
meaningful way, if data are highly heterogeneous or if 
study designs differ considerably, a tabular, graphical 
or narrative synthesis might be more useful [15].
Use of existing systematic reviews
It is estimated that a new full systematic review takes 
between six to 24 months, but using existing sys-
tematic reviews for the development of new evidence 
assessments can shorten this by one to two thirds [16]. 
The use of existing systematic reviews might therefore 
reduce efforts and costs, making the evidence assess-
ment process more efficient. Existing systematic 
reviews might complement the PRECEPT framework in 
various ways, e.g. by identifying studies, by answer-
ing full questions or by providing search strategies. 
Before using an existing systematic review, the need 
for an update should be evaluated. The process of 
identifying, assessing and applying existing systematic 
reviews should follow the steps proposed by Robinson 
et al. [17], and tools such as AMSTAR [18] or ROBIS [19] 
should be used to assess the methodological quality of 
existing systematic reviews.
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Step 3: Apply the evidence-grading system 
and document the results
PRECEPT recommends a standard approach that uses 
the GRADE methodology to evidence-grading across all 
four types of domains.
Quantitative evidence
According to GRADE, the certainty in the evidence indi-
cates the extent to which one can be confident that the 
estimate of effect is correct [4]. The units of analysis of 
GRADE are outcomes, meaning all assessments focus 
on the outcome of the intervention. At the beginning 
of the evidence review process, each outcome is rated 
from 1 to 9 regarding its importance to the decision, 
where outcomes rated 7 to 9 are regarded as ‘critical’, 
4 to 6 as ‘important’, and 1 to 3 as ‘of less importance’.
For questions related to burden of disease (domain 
(i), outcomes can be measures of incidence or preva-
lence, as well as mortality or disability-adjusted life 
years. For questions regarding risk factors (domain 
(ii)), outcomes are those variables that are dependent 
on the risk factor. For diagnostics (domain (iii)), true 
positives, true negatives, false positives and false 
negatives are regularly used as surrogates for sub-
sequent clinical outcomes. For questions regarding 
interventions (domain (iv)), outcomes are endpoints 
of clinical trials or observational studies. Taking the 
entire body of evidence, not an individual study, on 
one outcome into account, four levels of certainty in 
the evidence, i.e. confidence in the estimate of the 
effect, are applied to the results of the review:  very 
low, low, moderate and high. For interventions, RCTs 
are initially graded as high certainty, whereas all types 
of observational studies are classified as low certainty. 
Based on a defined set of criteria, decreasing (down-
grading) or increasing (upgrading) by one or two levels 
is possible. Five criteria are applied for downgrading: 
(i) risk of bias, (ii) inconsistency, (iii) indirectness, (iv) 
imprecision and (v) publication bias. Three criteria are 
used to upgrade the certainty in the evidence: (i) large 
effect, (ii) evidence for a dose-response relationship 
and (iii) all plausible confounding would have reduced 
the effect. The lowest quality level among all critical 
outcomes defines the overall level of evidence across 
all outcomes. PRECEPT proposes the following unified 
approach using GRADE for all four domains (Figure 4), 
which is consistent with the current GRADE approach 
[4,20-22]:
i. For each body of evidence related to an outcome, 
an initial rating of the certainty in the evidence is per-
formed. For some of the domains, this initial rating 
depends on study design.
ii. Risk of bias is assessed using the appropriate QAT for 
the individual studies (see Step 2). A judgment about 
the risk of bias is made for the body of evidence, and 
evidence certainty can be downgraded, if necessary.
iii. Thereafter, the other GRADE criteria for downgrad-
ing the certainty in the evidence (inconsistency, indi-
rectness, imprecision, publication bias) are applied.
iv. For the domains of ’intervention studies’ and ‘risk 
factor studies’, upgrading of the certainty in the evi-
dence is possible, according to the criteria introduced 
by GRADE. Evidence certainty should usually not be 
up graded after having been downgraded. It is cur-
rently unclear whether and how upgrading criteria are 
applicable to bodies of evidence on prevalence and 
diagnostics.
Qualitative evidence
For rating the evidence certainty of qualitative studies, 
PRECEPT proposes to assess limitations in the indi-
vidual studies using the appropriate QATs. In addition, 
users of PRECEPT might consider the GRADE–CERQual 
(Confidence in the Evidence from Reviews of Qualitative 
research) approach for assessing the confidence of evi-
dence from reviews of qualitative research [23].
Step 4: Prepare an evidence summary
At the end of the evidence appraisal process, a nar-
rative evidence summary for communication of the 
results should be prepared. The following points should 
be captured: (i) the overall question, which describes 
the key question of the review, (ii) detailed questions, 
which lists the questions addressed by the review, 
and (iii) the volume of evidence, which describes the 
studies identified during the review, and (iv) the evi-
dence statement and grading, which summarises the 
evidence which was identified by the review and the 
results of the grading process.
 
Conclusion
Over the past three years, the PRECEPT team has devel-
oped this framework for the assessment of evidence in 
the field of infectious disease epidemiology, preven-
tion and control. Currently, the application of the frame-
work is being tested in other systematic reviews and 
projects [16,24]. Furthermore, a consultation process 
will be carried out to obtain feedback and collect sug-
gestions for improvement. This process might lead to 
further refinements and adaptations of the framework.
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